Arcutis Biotherapeutics, Inc.
ARQTNASDAQHealthcare● Active
$21.26
+$0.03(+0.16%)
Market Cap$2.7B
P/E Ratio—
52W High$31.77
52W Low$12.72
Arcutis Biotherapeutics, Inc. (ARQT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARQT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.38B | $0.20B | $0.06B | $0.00B | $0.00B |
| Cost of Revenue | $0.04B | $0.02B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.34B | $0.18B | $0.05B | $0.00B | ($0.00B) |
| Gross Margin %(computed) | 90.24% | 90.27% | 91.63% | 79.54% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.08B | $0.11B | $0.18B | $0.15B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.06B |
| Total Operating Expenses | $0.35B | $0.31B | $0.30B | $0.30B | $0.21B |
| Operating Income | ($0.01B) | ($0.13B) | ($0.24B) | ($0.30B) | ($0.21B) |
| Operating Margin %(computed) | -3.25% | -65.33% | -404.49% | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.03B | $0.03B | $0.02B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.14B) | ($0.26B) | ($0.31B) | ($0.21B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.14B) | ($0.26B) | ($0.31B) | ($0.21B) |
| Net Margin %(computed) | -4.29% | -71.25% | -439.79% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.17 |
| Wtd Avg Shares | 0.13B | 0.12B | 0.07B | 0.06B | 0.05B |
| EBITDA | $0.00B | ($0.11B) | ($0.23B) | ($0.29B) | ($0.21B) |
| EBITDA Margin %(computed) | 0.66% | -55.78% | -381.56% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Arcutis Biotherapeutics, Inc. data
About Arcutis Biotherapeutics, Inc. (ARQT) Income Statement
Arcutis Biotherapeutics, Inc. (ARQT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ARQT reported revenue of $0.38B, gross profit of $0.34B (gross margin 90.24%), and net income of ($0.02B) — a net profit margin of -4.29%.
Frequently asked questions
ARQT · 4 questionsArcutis Biotherapeutics, Inc. (ARQT) reported revenue of $0.38B for 2025, up 91.3% year-over-year.
ARQT revenueARQT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08